JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v10i3.14391ArticleCurrent Status of Antidepressant Drug Research and Development in China: A Feature Analysis Based on Drug Clinical Trial Registration and Information Disclosure Platformhttps://artdesignp.com/journal/JCNR/10/3/10.26689/jcnr.v10i3.14391LiuZhe,ZhangYurong,WangLi,WangXin,XuRui20261032026-04-03Objective: To systematically review the clinical trial data of registered antidepressant drugs in China, conducted an in-depth analysis of their current status and development trends, and provided reference for the research and development of antidepressants. Methods: Clinical trials of registered antidepressant drugs registered from April 16,2013, to December 31,2025, were searched. The development status of antidepressant drug clinical trials in China was analyzed from various aspects, including drug types, indications, trial classification, phase, and design types. Results: A total of 675 trials were included, comprising 667 domestic multicenter trials and 8 international multicenter trials. Among them, chemical drugs accounted for 96.0%, while biological products were absent. There were 500 bioequivalence studies (74.1%), with Phase II and III trials employing parallel group, randomized, and double-blind designs. 501 (74.2%) clinical trials provided trial injury insurance for participants, and research resources were concentrated in leading psychiatric specialty hospitals. Conclusion: Although the overall development of antidepressant drug clinical trials in China has shown a steady trend, the number of international multicenter trials remains significantly low, while bioequivalence studies and early exploratory trials are more prevalent. Future efforts should focus on strengthening international cooperation and exchange, as well as innovative drug development, to accelerate the fulfillment of clinical needs for patients with depression in China.

Cui L, Li S, Wang S, et al., 2024, Major Depressive Disorder: Hypothesis, Mechanism, Prevention and Treatment. Signal Transduction and Targeted Therapy, 9(1): 30.

World Health Organization, 2025, Depressive Disorder (Depression), visited on 2025-11-12, https://www.who.int/health-topics/depression.

Lu J, Xu X, Huang Y, et al., 2021, Prevalence of Depressive Disorders and Treatment in China: A Cross-Sectional Epidemiological Study. Lancet Psychiatry, 8(11): 981–990.

Racine N, McArthur B, Cooke J, et al., 2021, Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-Analysis. JAMA Pediatrics, 175(11): 1142–1150.

Center for Drug Evaluation, National Medical Products Administration, 2020, Technical Guidelines for Clinical Trials of Antidepressant Drugs, visited on 2025-12-2, https://www.ydcdei.org.cn/news/show/1218168788969861120?from=%E8%A6%81%E9%97%BB%E5%8A%A8%E6%80%81 .

Xiang Y, Ni P, Tao M, et al., 2025, Exploring the Antidepressant Mechanism of Malt Ethanol Extract in Rats Subjected to Chronic Unpredictable Stress Based on Gut Microbiota. Herald of Medicine, 44(8): 1199–1207.

Center for Drug Evaluation, National Medical Products Administration, 2020, Measures for the Administration of Drug Registration (Revised in 2020). Chinese Journal of Drug Evaluation, 12(3): 265–280.

Donello J, McIntyre R, Pickel D, et al., 2025, Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor. Pharmaceuticals, 18(2): 157.

Jing R, Ge Q, Shao L, 2025, Research Progress on the Development of Rapid-Acting Antidepressants Targeting Glutamatergic Receptors. Progress in Pharmaceutical Sciences, 49(11): 948–957.

Zheng Y, Liu J, Wang Z, et al., 2025, Key Points and Recommendations for Reports from Data Monitoring Committees in Clinical Trials. Chinese Journal of Evidence-Based Medicine, 25(7): 850–855.

FDA, 2006, Guidance for Clinical Trial Sponsors Establishment and Operation of Clinical Trial Data Monitoring Committees, visited on 2025-12-11, https://www.fda.gov/media/75398/download.

Wang J, Feng B, Xu S, et al., 2024, Investigation and Analysis of the Utilization of Clinical Trial Insurance in China. Chinese Journal of New Drugs, 33(24): 2587–2593.

Zhang G, Yang Y, Zhao R, 2023, Analysis of Clinical Trials of Drugs for Hemophilia in Children in China from 2017 to 2021. Chinese Journal of Clinical Pharmacology, 39(1): 118–121.

Wang M, Wang X, Li Y, et al., 2024, Impact of Consistency Evaluation on the Generic Drug Industry in China. Chinese Journal of Pharmaceutical Industry, 55(11): 1583–1588.

Qiu B, Du R, Zhang Y, et al., 2026, Analysis of the Current Status of Clinical Trials of Drugs for Migraine Treatment in China. Herald of Medicine: 1–12.